Genoa Healthcare recently hosted a webinar where Senior Product Manager Blake Shoemaker, PharmD, discussed long-acting injectables (LAIs) in practice. Watch the recording below for an overview on benefits, challenges and best practices for incorporating behavioral health LAIs in treatment plans.
Have questions about LAIs or want to learn how partnering with Genoa can support your staff and consumers? Fill out the form below and we’ll be in touch.
"*" indicates required fields
Genoa Healthcare recently hosted a webinar where Senior Product Manager Blake Shoemaker, PharmD, discussed long-acting injectables (LAIs) in practice. Watch the recording below for an overview on benefits, challenges and...
1. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH. 2. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH....
Drug manufacturers began implementing restrictions for 340B pricing in 2020, citing alleged misuse by safety-net providers and explosive growth of the 340B Drug Pricing Program. Since then, restrictions for the...
Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...